Dashboard/CRBU/CB-010/event

InterimInterim Analysis

CB-010 ANTLER Phase 1 Dose-Expansion Update

CRBU·CB-010·B-cell Non-Hodgkin Lymphoma·

Phase 2

·NCT05023239

current best date

'26

QTR5 months

Takeaway

Updated Phase 1 dose-expansion data for CB-010 — an allogeneic (off-the-shelf) CD19 CAR-T — in relapsed/refractory B-cell lymphoma. Reference benchmark: autologous CAR-Ts (Yescarta, Breyanzi). Watch: complete-response rate, durability past 6 months, lymphodepletion-related safety.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~14%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAallogeneic CRISPR-edited anti-CD19 CAR-T

CB-010 is an allogeneic (off-the-shelf) CAR-T cell therapy developed by Caribou Biosciences for relapsed or refractory B-cell non-Hodgkin lymphoma. Using Caribou's chRDNA gene-editing platform, donor T cells are engineered to express a CD19-targeting chimeric antigen receptor and edited to reduce immune markers that would trigger rejection in a different patient, enabling a single manufacturing run to supply multiple patients. Unlike autologous CAR-T therapies (Yescarta, Breyanzi), which require 3–4 weeks of custom manufacturing per patient, CB-010 is available immediately as a stockpiled product; Phase 1 dose-expansion data are being presented in 2026.

Indication

Oncology - Heme

B-cell Non-Hodgkin Lymphoma

MeSH · D016393

No primer in glossary yet.

Trial

active

NCT05023239 ↗

ANTLER Phase 1 CB-010 in r/r B-NHL

Sector base rates · reference data

historical record · not prediction

of 1 historical Phase 2 readouts in Oncology - Heme: 1 positive, 0 mixed, 0 negative.

Positive

1/ 1

100%

Mixed

0/ 1

Negative

0/ 1

positive rate 100% · primary endpoint hit rate 100%

Reference data · comparable readouts

How Ph2 readouts in Oncology - Heme have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

1/1

100% in record

Primary endpoint hit

100%

across 1 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

mosunetuzumab

RHHBY · r/r FL

Ph2 · Jun 2022positiveCR rate 60%conference

pirtobrutinib (BRUIN-321)

LLY · CLL

Ph3 · Dec 2024positivePFS HR 0.54PR

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

4 peers in Oncology - Heme · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Next catalyst
BEAM-101	BEAM	cell therapy	base editing of HBG1/2 to reactivate fetal hemoglobin	READOUT · Dec 26
reni-cel	EDIT	cell therapy	CRISPR/Cas12a HBG1/2 promoter edit	CONFERENCE · May 26
CASGEVYexagamglogene autotemcel	CRSP	cell therapy	CRISPR/Cas9 BCL11A enhancer edit	CONFERENCE · Dec 26
JAKAFIruxolitinib	INCY	small molecule	JAK1/JAK2 inhibitor	READOUT · Sep 26

Disclosure trail

1 observation · sorted by confidence

Mar 12, 2026·1mo agopinned · highest confidence
MED confPR
top claim
Q4'26
QTR
“An updated dose-expansion dataset from the ANTLER Phase 1 study of CB-010 in r/r B-cell NHL is anticipated in Q4 2026.”
conf 82%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.